Full text
Earnings transcript
Read the complete earnings call transcript.
HOLX
Hologic, Inc.
$75.65
0.05
(0.07%)
| Exchange: | NASDAQ |
| Market Cap: | 16.888B |
| Shares Outstanding: | 8.712M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Paul Malenchini | |||||
| Full Time Employees: | 7063 | |||||
| Address: |
| |||||
| Website: | https://www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women’s health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 4,030,400 | 4,030,300 | 4,100,500 |
| Gross Profit | 2,071,500 | 2,227,800 | 2,501,100 |
| EBITDA | 1,110,600 | 1,296,200 | 1,023,700 |
| Operating Income | 668,400 | 882,600 | 714,300 |
| Net Income | 456,000 | 789,500 | 565,700 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 9,139,300 | 9,156,000 | 9,014,900 |
| Total Liabilities | 4,122,400 | 4,026,000 | 3,967,000 |
| Total Stockholders Equity | 5,016,900 | 5,130,000 | 5,047,900 |
| Total Debt | 2,904,100 | 2,658,000 | 2,626,800 |
| Cash and Cash Equivalents | 2,722,500 | 2,160,200 | 1,959,500 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,051,200 | 1,285,200 | 1,057,099.999 |
| Capital Expenditure | -150,200 | -140,200 | -58,800 |
| Free Cash Flow | 901,000 | 1,145,000 | 998,299.999 |
| Net Income | 456,000 | 789,500 | 565,700 |
| Net Change in Cash | 416,200 | -595,500 | -200,700 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,885,286.903 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 4,968,586.613 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 4,932,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,891,753.579 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,924,010.134 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,909,842.521 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,396,037.223 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,427,071.147 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,413,440.355 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,079,131.818 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,097,532.246 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,089,450.473 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 5.950 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 6.010 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 5.880 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates HOLX intrinsic value between $70.36 – $70.92 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about HOLX valuation
Is Hologic, Inc. (HOLX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Hologic, Inc. (HOLX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is HOLX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HOLX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is HOLX’s P/E ratio?
You can see HOLX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for HOLX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is HOLX a good long-term investment?
Whether HOLX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
HOLX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.07
Trading Metrics:
| Open: | 75.63 | Previous Close: | 75.6 | |
| Day Low: | 75.55 | Day High: | 75.66 | |
| Year Low: | 51.9 | Year High: | 75.78 | |
| Price Avg 50: | 75.27 | Price Avg 200: | 71.22 | |
| Volume: | 3.098M | Average Volume: | 4.486M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
